Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma

Nishimura, Goshi; Taguchi, Takahide; Takahashi, Masahiro; Shiono, Osamu; Komatsu, Masanori; Sano, Daisuke; Yabuki, Kenichiro; Arai, Yasuhiro; Takahashi, Hideaki; Hata, Masaharu

doi:10.1007/s00280-016-3052-4

Cited by 7 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concurrent chemotherapy regimens were decided on the basis of age and/or comorbidity. The chemotherapy regimens were as follows: the TPF regimen consisting of docetaxel, cis-platinum, and 5-uorouracil 13,14) ; the TPE regimen consisting of docetaxel, cis-platinum, and cetuximab 15) ; the cis-platinum regimen 16) ; the cetuximab regimen 17) ; and the S-1 regimen consisting of the oral administration of S-1 18) . Induction chemotherapy was performed prior to the de nitive surgery or chemoradiotherapy using a combination of docetaxel, cis-platinum, and 5-uorouracil 19) .…”

Section: Treatment Methodsmentioning

confidence: 99%

Risk factors of secondary cancer in laryngeal, oropharyngeal, or hypopharyngeal cancer after definitive therapy

Nishimura,

Takahashi,

Sano

et al. 2023

Int J Clin Oncol

Self Cite

View full text Add to dashboard Cite

BackgroundOur previous research showed that a high rate of secondary carcinogenesis is observed during follow-up after transoral surgery in patients with early-stage laryngeal, oropharyngeal, and hypopharyngeal cancers.We speculate that the contributing factors are alcohol drinking, smoking, and aging; however, we could not provide clear evidence. In this study, we aimed to identify the risk factors for secondary carcinogenesis in patients with these cancers, particularly factors associated with drinking and/or smoking. MethodsThe medical records of all-stage laryngeal, oropharyngeal, and hypopharyngeal cancer patients who had undergone de nitive treatment were retrospectively analyzed. Assessments included visual and endoscopic observations of the primary site, enhanced cervical CT or US of the primary site and regional lymph nodes, PET-CT, and enhanced whole-body CT. Clinical characteristics were compared in patients with and without secondary carcinogenesis and in patients with hypopharyngeal cancer and patients with other cancers. ResultsHypopharyngeal cancer was an independent risk factor for secondary cancer. The 5-year incidence rate of secondary cancer was 25.5%, 28.6%, and 41.2% in laryngeal, oropharyngeal, and hypopharyngeal cancers, respectively. Radiotherapy was de ned as an independent risk factor in hypopharyngeal cancer patients with secondary cancers. No direct correlation was found between secondary carcinogenesis and alcohol consumption, smoking, or aging. ConclusionsPatients with hypopharyngeal cancer require close follow-up as they are at high risk of developing secondary cancer, possibly because out-of-eld radiation exposure may induce systemic secondary carcinogenesis in hypopharyngeal cancer patients with genetic abnormality induced by alcohol consumption.

show abstract